Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Haynes, Barton F., Gilbert, Peter B., McElrath, M. Juliana, Zolla-Pazner, Susan, Tomaras, Georgia D., Alam, S. Munir, Evans, David T., Montefiori, David C., Karnasuta, Chitraporn, Sutthent, Ruengpueng, Liao, Hua-Xin, DeVico, Anthony L., Lewis, George K., Williams, Constance, Pinter, Abraham, Fong, Youyi, Janes, Holly, DeCamp, Allan, Huang, Yunda, Rao, Mangala, Billings, Erik, Karasavvas, Nicos, Robb, Merlin L., Ngauy, Viseth, de Souza, Mark S., Paris, Robert, Ferrari, Guido, Bailer, Robert T., Soderberg, Kelly A., Andrews, Charla, Berman, Phillip W., Frahm, Nicole, De Rosa, Stephen C., Alpert, Michael D., Yates, Nicole L., Shen, Xiaoying, Koup, Richard A., Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Michael, Nelson L., Kim, Jerome H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3371689/
https://ncbi.nlm.nih.gov/pubmed/22475592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1113425
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge